Placebo-controlled trial of rituximab in IgM anti-myelin–associated glycoprotein neuropathy

OBJECTIVE: To determine whether rituximab 375 mg/m(2) was efficacious in patients with immunoglobulin M (IgM) anti-myelin–associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG demyelinating neuropathy). METHODS: Fifty-four patients with IgM anti-MAG demyelinating neuropathy were en...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Léger, Jean-Marc, Viala, Karine, Nicolas, Guillaume, Créange, Alain, Vallat, Jean-Michel, Pouget, Jean, Clavelou, Pierre, Vial, Christophe, Steck, Andreas, Musset, Lucile, Marin, Benoit
Médium: Artigo
Jazyk:Inglês
Vydáno: Lippincott Williams & Wilkins 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3721095/
https://ncbi.nlm.nih.gov/pubmed/23667063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318296e92b
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky